Nkarta Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.6
- Today's High:
- $1.81
- Open Price:
- $1.72
- 52W Low:
- $1.55
- 52W High:
- $14.57
- Prev. Close:
- $1.71
- Volume:
- 678363
Company Statistics
- Market Cap.:
- $86.83 million
- Book Value:
- 6.482
- Revenue TTM:
- $385
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-36220000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -18.28%
- Return on Equity TTM:
- -33.84%
Company Profile
Nkarta Inc had its IPO on 2020-07-10 under the ticker symbol NKTX.
The company operates in the Healthcare sector and Biotechnology industry. Nkarta Inc has a staff strength of 169 employees.
Stock update
Shares of Nkarta Inc opened at $1.72 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.6 - $1.81, and closed at $1.65.
This is a -3.51% slip from the previous day's closing price.
A total volume of 678,363 shares were traded at the close of the day’s session.
In the last one week, shares of Nkarta Inc have slipped by -6.78%.
Nkarta Inc's Key Ratios
Nkarta Inc has a market cap of $86.83 million, indicating a price to book ratio of 0.9096 and a price to sales ratio of 999999.9999.
In the last 12-months Nkarta Inc’s revenue was $385 with a gross profit of $-36220000 and an EBITDA of $-133386000. The EBITDA ratio measures Nkarta Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Nkarta Inc’s operating margin was 0% while its return on assets stood at -18.28% with a return of equity of -33.84%.
In Q2, Nkarta Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Nkarta Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.54 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Nkarta Inc’s profitability.
Nkarta Inc stock is trading at a EV to sales ratio of 999999.9999 and a EV to EBITDA ratio of -0.52. Its price to sales ratio in the trailing 12-months stood at 999999.9999.
Nkarta Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $429.04 million
- Total Liabilities
- $26.61 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $10.33 million
- Dividend Payout Ratio
- 0%
Nkarta Inc ended 2024 with $429.04 million in total assets and $0 in total liabilities. Its intangible assets were valued at $429.04 million while shareholder equity stood at $317.98 million.
Nkarta Inc ended 2024 with $0 in deferred long-term liabilities, $26.61 million in other current liabilities, 5000.00 in common stock, $-382035000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $29.12 million and cash and short-term investments were $280.75 million. The company’s total short-term debt was $6,050,000 while long-term debt stood at $0.
Nkarta Inc’s total current assets stands at $286.74 million while long-term investments were $18.73 million and short-term investments were $251.64 million. Its net receivables were $0 compared to accounts payable of $3.01 million and inventory worth $0.
In 2024, Nkarta Inc's operating cash flow was $0 while its capital expenditure stood at $10.33 million.
Comparatively, Nkarta Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.65
- 52-Week High
- $14.57
- 52-Week Low
- $1.55
- Analyst Target Price
- $19.63
Nkarta Inc stock is currently trading at $1.65 per share. It touched a 52-week high of $14.57 and a 52-week low of $14.57. Analysts tracking the stock have a 12-month average target price of $19.63.
Its 50-day moving average was $1.97 and 200-day moving average was $4.26 The short ratio stood at 7.37 indicating a short percent outstanding of 0%.
Around 704.9% of the company’s stock are held by insiders while 8817.6% are held by institutions.
Frequently Asked Questions About Nkarta Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company’s approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.